Liver Study Unit, Department of Veterans Affairs Medical Center, San Francisco, CA, USA.
J Cardiovasc Pharmacol Ther. 2010 Jun;15(2):190-5. doi: 10.1177/1074248409360356. Epub 2010 Mar 3.
Ischemic pre- and postconditioning protect ex vivo rat hearts from ischemia/reperfusion injury by promoting the release of cardioprotective agents by an unknown mechanism. Because P2X( 7) purinergic receptors are known to combine with pannexin-1 to form channels that allow adenosine triphosphate (ATP) release from cells, we hypothesized that these channels have a role in the release of multiple cardioprotectants during ischemic preconditioning (IPC). Addition of either a pannexin-1 hemichannel blocker (5 micromol/L carbenoxolone [CBX] or 0.4 micromol/L mefloquine [MF]) or a selective antagonist of the rat P2X(7) purinergic receptor (2 micromol/L brilliant blue G [BBG]) blocked IPC. These antagonists also blocked ischemic postconditioning. Preconditioning by exogenous addition of either sphingosine-1-phosphate or adenosine was not blocked by either CBX or BBG, indicating that they only affected the release of endogenous mediators, not any subsequent steps. To determine if only ATP release was mediated by pannexin-1/P2X(7) channels, we added an extra cycle of IPC to release sufficient quantities of additional cardioprotectants to eliminate the dependence on adenosine derivatives. This did not override the inhibition of IPC by CBX or MF, suggesting that the channel mediates the release of multiple cardioprotectants. Inhibitors of other P2X receptors, P2Y receptors, or connexins did not affect IPC. We conclude that a pannexin-1/P2X(7) channel is responsible for the release of cardioprotectants induced by ischemic pre- and postconditioning.
缺血预处理和后处理通过未知机制促进心脏保护性物质的释放来保护离体大鼠心脏免受缺血/再灌注损伤。由于已知 P2X(7)嘌呤能受体与连接蛋白-1 结合形成通道,使三磷酸腺苷 (ATP) 从细胞中释放,我们假设这些通道在缺血预处理 (IPC) 期间多种心脏保护剂的释放中起作用。添加连接蛋白-1 半通道阻滞剂(5 微摩尔/升 carbenoxolone [CBX]或 0.4 微摩尔/升 mefloquine [MF])或大鼠 P2X(7)嘌呤能受体的选择性拮抗剂(2 微摩尔/升 brilliant blue G [BBG])均可阻断 IPC。这些拮抗剂也阻断了缺血后处理。外源性添加鞘氨醇-1-磷酸或腺苷的预处理不受 CBX 或 BBG 的阻断,表明它们仅影响内源性介质的释放,而不影响任何后续步骤。为了确定是否只有 ATP 释放由连接蛋白-1/P2X(7)通道介导,我们增加了一个额外的 IPC 循环,以释放足够数量的额外心脏保护剂来消除对腺苷衍生物的依赖。这并没有克服 CBX 或 MF 对 IPC 的抑制作用,这表明该通道介导了多种心脏保护剂的释放。其他 P2X 受体、P2Y 受体或连接蛋白抑制剂均不影响 IPC。我们得出结论,连接蛋白-1/P2X(7)通道负责缺血预处理和后处理诱导的心脏保护剂的释放。